Want to see SE:ACTI full AI Analyst Report?
ACTI Stock Chart & Stats
kr0.04
<kr0.01(1.97%)
At close: 4:00 PM EST
kr0.04
<kr0.01(1.97%)
Day’s Range― - ―
52-Week Rangekr3.70 - kr20.07
Previous CloseN/A
Volume903.68K
Average Volume (3M)4.56M
Market Cap
kr148.41M
Enterprise Valuekr15.45B
Total Cash (Recent Filing)kr53.30M
Total Debt (Recent Filing)kr100.00K
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding26,360,670
10 Day Avg. Volume2,218,804
30 Day Avg. Volume4,558,826
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)111.47
Price to Sales (P/S)0.00
P/FCF Ratio-191.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr21.50M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetVery low leverage meaningfully reduces financial risk and preserves optionality for funding R&D or partnering. This durable credit strength lowers default risk, improves negotiation power with partners and investors, and supports operations for several quarters absent large new cash needs.
Narrowing Losses Over TimeA materially smaller net loss versus prior years signals improved cost control or program prioritization. Sustained narrowing of losses enhances runway, reduces the pace of equity erosion, and increases the likelihood management can reach partnering or financing milestones without immediate drastic measures.
Focused R&D And Partnership-driven Commercialization ModelA strategy centered on developing clinical-stage assets and then partnering for late-stage development is structurally capital-efficient. It lets the company concentrate resources on discovery and early trials while transferring commercialization costs and execution risk to partners, a durable model for small biotech firms.
Bears Say
No Revenue / Persistent Heavy LossesLack of revenue means the business cannot self-fund operations and remains fully reliant on external financing or licensing. Persistent losses undermine long-term viability if new financing or partner deals are delayed, increasing dilution or the need to cut programs.
Sustained Negative Operating And Free Cash FlowConsistent negative operating and free cash flow at meaningful magnitudes creates ongoing funding pressure. Over multiple quarters this requires repeated financing or deals; absent those, the company faces constrained operations, delayed development timelines, or accelerated balance sheet erosion.
Eroding Equity BaseA decline in shareholders' equity reflects cumulative losses and reduces financial flexibility. Continued erosion shortens the runway for R&D, weakens ability to absorb shocks, and increases urgency for financing or partnerships, raising execution risk for multi-quarter development programs.
Active Biotech AB News
ACTI FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest stock price was kr3.70 and its highest was kr20.07 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is kr148.41M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is Aug 20, 2026 which is in 47 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on May 07, 2026. The company reported -kr0.319 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.319.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 26,360,670 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of -kr0.319 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.833%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in SE:ACTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Medivir AB
―
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―